Director Dealings: In the know at Nanoco?

TECHNOLOGY company Nanoco has enjoyed a sparkling debut since joining the AIM market earlier this year.

Shares in the Manchester-based university spinout, which makes fluorescent nano-crystals used by electronics companies in LEDs and electronic displays, have more than doubled in the past month.

In February the company was bought in a reverse takeover deal by AIM-listed investment company Evolutec which valued the business at 38.6m.

Despite the share price rise, Gordon Hall, a non-executive director and a well-known figure in the technology sector, has decided to take his first stake in the company with the purchase of 100,000 ordinary shares at a price of 44p.

&#149 Two directors at North Sea-focused oil group Xcite Energy, have upped their stakes. Non-executive director Timothy Jones bought 50,000 shares at 31p and Stephen Kew, exploration and development director, bought 14,285 shares at 32p each. Several senior managers at the Banchory-based company bought a total of just under 100,000 shares at 32p each.

&#149 Christopher Smith, an executive director at pension trusts group Law Debenture Corp, has bought 25,000 shares at 243p each in the company.

&#149 Dr Michael Asbury, a non-executive director of ProStrakan Group, bought 97,654 shares in the company at 80.75p each.

&#149 Gareth Bullock, director in charge of growth for much of Standard Chartered's international operations, has sold shares for the second time this year. He disposed of around 19,000 shares at 1,175p each following the sale of 26,000 shares in March. He retains a stake of more than 200,000 shares in the banking group.

&#149 Dr Erling Sundrehagen, chief scientific officer of Dundee-based medical diagnostics group Axis-Shield, has sold 50,000 shares at 296p each to reduce his holding to 179,645.

&#149 Mark Tincknell, chairman of social housing group Connaught, has sold 650,000 shares at 355p each to reduce his stake to 678,000 shares.